A. Poklepovic

J. Luke, J. Mehnert, A. Poklepovic, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Insulin activates protein kinases C-zeta and C-lambda by an autophosphorylation-dependent mechanism and stimulates their translocation to GLUT4 vesicles and other membrane fractions in rat adipocytes.

A. Toker, R. Farese, J. Moscat, 1999, The Journal of biological chemistry.

BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours

J. Ensor, M. Malhotra, P. Kasi, 2022, BMJ Open.

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies

P. Dent, L. Booth, A. Poklepovic, 2019, Immunometabolism.

Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib.

D. V. Von Hoff, Yong Zhou, J. Hancock, 2021, Biochemical pharmacology.

Population-based risk factors and resource utilization for HCC: US perspective

A. Sanyal, A. Poklepovic, É. Moyneur, 2010, Current medical research and opinion.

PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells

M. Malkin, P. Dent, S. Grant, 2014, Cancer biology & therapy.

AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication

P. Dent, J. Rayner, Jane L. Roberts, 2020, Biochemical Pharmacology.

Neratinib kills B‐RAF V600E melanoma via ROS‐dependent autophagosome formation and death receptor signaling

J. Kirkwood, P. Dent, A. Poklepovic, 2021, Pigment cell & melanoma research.

Sorafenib/Regorafenib and Lapatinib Interact to kill CNS Tumor Cells

P. Dent, S. Grant, A. Poklepovic, 2015, Journal of cellular physiology.

Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic

P. Dent, Jane L. Roberts, A. Poklepovic, 2016, Front. Oncol..

Signaling alterations caused by drugs and autophagy.

J. Hancock, P. Dent, A. Poklepovic, 2019, Cellular signalling.

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

P. Dent, A. Lalani, R. Cutler, 2017, Oncotarget.

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

A. Balar, Ping Liu, I. Durán, 2019, Journal of Translational Medicine.

OSU‐03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood–Brain Barrier: Implications for Anti‐Cancer Therapies

P. Dent, Jane L. Roberts, A. Poklepovic, 2015, Journal of cellular physiology.

Sorafenib/Regorafenib and Phosphatidyl Inositol 3 Kinase/Thymoma Viral Proto-Oncogene Inhibition Interact to Kill Tumor Cells

P. Dent, S. Grant, N. Cruickshanks, 2013, Molecular Pharmacology.

The development of multi-kinase inhibitors as pancreatic cancer therapeutics

J. Hancock, P. Dent, A. Poklepovic, 2021, Anti-cancer drugs.

The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant

A. Aleshin, A. Poklepovic, A. Kasi, 2022, Case reports in obstetrics and gynecology.

HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells

P. Dent, S. Grant, N. Cruickshanks, 2014, Cancer biology & therapy.

Pazopanib and HDAC inhibitors interact to kill sarcoma cells

P. Dent, S. Grant, A. Poklepovic, 2014, Cancer biology & therapy.

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib

P. Dent, Jane L. Roberts, A. Poklepovic, 2019, Front. Oncol..

HDAC inhibitors enhance the immunotherapy response of melanoma cells.

J. Kirkwood, P. Dent, Jane L. Roberts, 2017, Oncotarget.

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo

J. Kirkwood, P. Dent, C. Sander, 2017, Oncotarget.

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy

P. Dent, S. Grant, N. Cruickshanks, 2013, Cancer biology & therapy.

3 Molecularly Targeted Therapy : Imatinib and Beyond

A. Poklepovic, P. Bose, 2017 .

Molecularly Targeted Therapy: Imatinib and Beyond

A. Poklepovic, P. Bose, 2012 .

Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?

I. Higginson, F. Strasser, S. Hurst, 2016, Journal of pain and symptom management.

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

V. Sondak, M. Ross, M. Atkins, 2023, The New England journal of medicine.

Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.

N. Ibrahim, C. Link, P. Dillon, 2020, JAMA oncology.

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.

Charles H. Yoon, A. Hauschild, James R. Anderson, 2019, Future oncology.

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma

John D. Roberts, P. Dent, R. Sterling, 2019, American journal of clinical oncology.

A phase 1 study of neoadjuvant chemotherapy followed by concurrent chemoradiation with gemcitabine, sorafenib, and vorinostat in pancreatic cancer.

P. Dent, K. Matin, E. Fields, 2021 .

Discovery of a ‘Grail-Shaped’ Drug: Ne-ratinib and the Downregulation of Mutant RAS

P. Dent, A. Poklepovic, Laurence A Booth, 2019, EMJ Oncology.

NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.

P. Dent, Jane L. Roberts, A. Poklepovic, 2017, Oncology signaling.

Kinase inhibitors: look beyond the label on the bottle

J. Hancock, P. Dent, A. Poklepovic, 2019, Cancer drug resistance.

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide

P. Dent, Jane L. Roberts, A. Poklepovic, 2016, Oncotarget.

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling

P. Dent, W. Mcguire, Jane L. Roberts, 2016, Oncotarget.

Not the comfy chair! Cancer drugs that act against multiple active sites

P. Dent, A. Poklepovic, Laurence A Booth, 2019, Expert opinion on therapeutic targets.

The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells

P. Dent, Jane L. Roberts, A. Poklepovic, 2018, Cancer biology & therapy.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells

P. Dent, A. Lalani, R. Cutler, 2018, Cancer biology & therapy.

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration

J. Kirkwood, P. Dent, A. Lalani, 2017, Oncotarget.

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.

J. Kirkwood, P. Dent, Jane L. Roberts, 2018, Advances in cancer research.

[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells

P. Dent, Jane L. Roberts, A. Poklepovic, 2017, Cancer biology & therapy.

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species

Jane L. Roberts, A. Poklepovic, Laurence A Booth, 2017, Oncotarget.

Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].

J. Hancock, P. Dent, A. Poklepovic, 2020, Cellular signalling.

Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells

D. Tuveson, J. Hancock, P. Dent, 2019, Oncogene.

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

J. Kirkwood, P. Dent, C. Sander, 2017, Cancer biology & therapy.

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo

P. Dent, T. Albers, Jane L. Roberts, 2016, Oncotarget.

Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress–Inducing Drugs

P. Dent, S. Grant, N. Cruickshanks, 2014, Molecular Cancer Therapeutics.

Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling

S. Spiegel, P. Dent, S. Grant, 2012, Cancer biology & therapy.

Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.

Edward J. Kim, L. Cope, Helen X. Chen, 2021, The Journal of clinical investigation.

Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.

V. Sondak, T. Karrison, D. Olson, 2020 .

550 ARTACUS: An open-label, multicenter, phase 1b/2 study of RP1 in solid organ transplant recipients with advanced cutaneous malignancies

G. Daniels, R. Coffin, T. Wise-Draper, 2021, Journal for ImmunoTherapy of Cancer.

Considering adjuvant therapy for stage II melanoma

J. Luke, A. Poklepovic, 2019, Cancer.

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

V. Sondak, T. Karrison, D. Olson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma

John D. Roberts, M. Ernstoff, V. Ramakrishnan, 2013, Investigational New Drugs.

Lapatinib and Obatoclax Kill Tumor Cells through Blockade of ERBB1/3/4 and through Inhibition of BCL-xL and MCL-1

P. Fisher, P. Dent, S. Grant, 2012, Molecular Pharmacology.

Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance

P. Dent, W. Mcguire, Jane L. Roberts, 2015, Cancer biology & therapy.

Targeted Next-Generation Sequencing Traces the Origin of a Poorly Differentiated Malignancy

M. Contos, Steven C. Smith, C. Dumur, 2017, AJSP: Reviews and Reports.

Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity

H. Bear, E. Repasky, Xiaofei Yu, 2021, Journal for ImmunoTherapy of Cancer.

Fingolimod Augments Monomethylfumarate Killing of GBM Cells

J. Hancock, P. Dent, Jane L. Roberts, 2020, Frontiers in Oncology.

Multiple Immunotherapy-Related Cardiovascular Sequelae

A. Poklepovic, Wendy J Bottinor, Ariel Sindel, 2022, CJC open.

Emerging therapeutic options for metastatic exocrine pancreatic cancer

Haeseong Park, A. Poklepovic, P. Bose, 2012 .

PDE5 Inhibitors Enhance Celecoxib Killing in Multiple Tumor Types

S. Spiegel, P. Dent, N. Cruickshanks, 2015, Journal of cellular physiology.

AR12 increases BAG3 expression which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy

E. Reiman, P. Dent, Jennifer Martinez, 2022, Aging.

The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.

P. Dent, Jane L. Roberts, A. Poklepovic, 2020, Cellular signalling.

Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.

P. Dent, A. Poklepovic, Laurence A Booth, 2020, Biochemical pharmacology.

Prognostic Value of Low Tumor Burden in Patients With Melanoma.

R. Carvajal, A. Poklepovic, 2018, Oncology.

Regulation of dimethyl-fumarate toxicity by proteasome inhibitors

P. Dent, N. Cruickshanks, Jane L. Roberts, 2014, Cancer biology & therapy.

A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer

H. Soares, Jongphil Kim, H. Sanoff, 2020, Cancer.

Valproate augments Niraparib killing of tumor cells

P. Dent, Jane L. Roberts, A. Poklepovic, 2018, Cancer biology & therapy.

(Curcumin+sildenafil) enhances the efficacy of 5FU and anti‐PD1 therapies in vivo

J. Hancock, P. Dent, Jane L. Roberts, 2020, Journal of cellular physiology.

HDAC inhibitors enhance the immunotherapy response of melanoma cells

J. Kirkwood, P. Dent, Jane L. Roberts, 2017, Oncotarget.

Immune Checkpoint Inhibitor Rechallenge in a Patient With Previous Fulminant Myocarditis.

A. Poklepovic, Wendy J Bottinor, Yiwei Hang, 2023, The American journal of cardiology.

Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancer

B. Ramaswamy, C. Shapiro, C. Isaacs, 2016 .

Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling

J. Hancock, P. Dent, Jennifer Martinez, 2020, Journal of cellular physiology.

588 Phase Ib study of the p38 inhibitor ARRY-614 with nivolumab, ipilimumab or nivolumab+ipilimumab in advanced solid tumors

D. Davar, Amy Rose, Y. Najjar, 2022, Regular and Young Investigator Award Abstracts.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells

P. Dent, A. Lalani, R. Cutler, 2018, Cancer biology & therapy.

Editor's Note: Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress–Inducing Drugs

P. Dent, S. Grant, N. Cruickshanks, 2019, Molecular Cancer Therapeutics.

Abstract 796: Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy

P. Dent, S. Grant, N. Cruickshanks, 2014 .

Automated determination of metastases in unstructured radiology reports for eligibility screening in oncology clinical trials

L. Penberthy, Valentina I Petkov, B. Dahman, 2013, Experimental biology and medicine.

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

A. Balar, Ping Liu, I. Durán, 2019, Journal of Translational Medicine.

Tumor cell p38 inhibition to overcome immunotherapy resistance

D. Davar, Y. Najjar, H. Skinner, 2023, Research square.

Population-based risk factors and resource utilization for HCC: US perspective

A. Sanyal, A. Poklepovic, É. Moyneur, 2010, Current medical research and opinion.

Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells.

Jane L. Roberts, A. Poklepovic, Laurence A Booth, 2023, Anti-cancer drugs.

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma

S. Radhakrishnan, Richard I. J. Kurupi, A. Banito, 2024, bioRxiv.

A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors

M. B. Tombes, A. Poklepovic, Sejal M. Kothadia, 2024, Anti-cancer drugs.

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo

J. Kirkwood, P. Dent, C. Sander, 2017, Oncotarget.